Fungal drug repurposed in fight against aggressive breast cancer
NCT ID NCT06802757
Summary
This study is testing if adding an existing antifungal drug, posaconazole, to standard chemotherapy and immunotherapy can improve treatment results for patients with triple-negative breast cancer before surgery. Researchers aim to see if this combination helps more patients achieve a complete response, meaning no detectable cancer is found in tissue removed during surgery. The trial will involve 72 newly diagnosed patients who will be randomly assigned to receive either the standard treatment or the standard treatment plus posaconazole.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.